{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T06:09:20Z","timestamp":1769321360545,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,12,14]],"date-time":"2014-12-14T00:00:00Z","timestamp":1418515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00535-014-1023-2","type":"journal-article","created":{"date-parts":[[2014,12,13]],"date-time":"2014-12-13T08:23:45Z","timestamp":1418459025000},"page":"894-902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Association of serum IFN-\u03bb3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection"],"prefix":"10.1007","volume":"50","author":[{"given":"Yoshihiko","family":"Aoki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumoto","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiyo","family":"Yoshio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yatsuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Hon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeko","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuji","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Yamagiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Korenaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiko","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namiki","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Kage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,14]]},"reference":[{"issue":"7","key":"1023_CR1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm.3184","volume":"19","author":"DL Thomas","year":"2013","unstructured":"Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19(7):850\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"1023_CR2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00535-005-1740-7","volume":"41","author":"N Hayashi","year":"2006","unstructured":"Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006;41(1):17\u201327.","journal-title":"J Gastroenterol"},{"issue":"20","key":"1023_CR3","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMra1213651","volume":"368","author":"TJ Liang","year":"2013","unstructured":"Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368(20):1907\u201317.","journal-title":"N Engl J Med"},{"issue":"21","key":"1023_CR4","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMe1403619","volume":"370","author":"TJ Liang","year":"2014","unstructured":"Liang TJ, Ghany MG. Therapy of hepatitis C\u2014back to the future. N Engl J Med. 2014;370(21):2043\u20137.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1023_CR5","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","volume":"56","author":"C Sarrazin","year":"2012","unstructured":"Sarrazin C, Hezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012;56(Suppl 1):S88\u2013100.","journal-title":"J Hepatol"},{"key":"1023_CR6","doi-asserted-by":"crossref","unstructured":"Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120\u20139.e18.","DOI":"10.1053\/j.gastro.2010.04.013"},{"issue":"7262","key":"1023_CR7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399\u2013401.","journal-title":"Nature"},{"issue":"10","key":"1023_CR8","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-\u03b1 and ribavirin therapy. Nat Genet. 2009;41(10):1100\u20134.","journal-title":"Nat Genet"},{"issue":"10","key":"1023_CR9","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-\u03b1 and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105\u20139.","journal-title":"Nat Genet"},{"issue":"6","key":"1023_CR10","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","volume":"131","author":"T Marcello","year":"2006","unstructured":"Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons \u03b1 and \u03bb inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131(6):1887\u201398.","journal-title":"Gastroenterology"},{"issue":"5","key":"1023_CR11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.coi.2011.07.007","volume":"23","author":"SV Kotenko","year":"2011","unstructured":"Kotenko SV. IFN-\u03bbs. Curr Opin Immunol. 2011;23(5):583\u201390.","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"1023_CR12","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1053\/j.gastro.2011.12.055","volume":"142","author":"E Thomas","year":"2012","unstructured":"Thomas E, Gonzalez VD, Li Q, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2012;142(4):978\u201388.","journal-title":"Gastroenterology"},{"issue":"1","key":"1023_CR13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1872-034X.2009.00634.x","volume":"40","author":"H Kumada","year":"2010","unstructured":"Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010;40(1):8\u201313.","journal-title":"Hepatol Res"},{"issue":"4","key":"1023_CR14","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","volume":"54","author":"MG Ghany","year":"2011","unstructured":"Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433\u201344.","journal-title":"Hepatology"},{"key":"1023_CR15","doi-asserted-by":"crossref","unstructured":"Bedossa P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20(1):15\u201320.","DOI":"10.1002\/hep.1840200104"},{"key":"1023_CR16","doi-asserted-by":"crossref","unstructured":"Ogawa E, Furusyo N, Shimizu M, et al. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C. Antivir Ther. 2014. doi: 10.3851\/IMP2805 .","DOI":"10.3851\/IMP2805"},{"key":"1023_CR17","doi-asserted-by":"crossref","unstructured":"Teshale E, Lu M, Rupp LB, et al. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS). J Viral Hepat. 2014;21(12):917\u201320.","DOI":"10.1111\/jvh.12279"},{"issue":"5","key":"1023_CR18","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1128\/JCM.02139-10","volume":"49","author":"K Ito","year":"2011","unstructured":"Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon\/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011;49(5):1853\u201360.","journal-title":"J Clin Microbiol"},{"issue":"11","key":"1023_CR19","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1872-034X.2012.01032.x","volume":"42","author":"M Sugiyama","year":"2012","unstructured":"Sugiyama M, Kimura T, Naito S, et al. Development of specific and quantitative real-time detection PCR and immunoassays for \u03bb3-interferon. Hepatol Res. 2012;42(11):1089\u201399.","journal-title":"Hepatol Res"},{"issue":"6","key":"1023_CR20","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/hep.21606","volume":"45","author":"AC Melton","year":"2007","unstructured":"Melton AC, Yee HF. Hepatic stellate cell protrusions couple platelet-derived growth factor-BB to chemotaxis. Hepatology. 2007;45(6):1446\u201353.","journal-title":"Hepatology"},{"issue":"3","key":"1023_CR21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/hep.22707","volume":"49","author":"HE Wasmuth","year":"2009","unstructured":"Wasmuth HE, Tag CG, Van de Leur E, et al. The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. Hepatology. 2009;49(3):775\u201380.","journal-title":"Hepatology"},{"issue":"11","key":"1023_CR22","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1872-034X.2010.00718.x","volume":"40","author":"S Ogawa","year":"2010","unstructured":"Ogawa S, Ochi T, Shimada H, et al. Anti-PDGF-B monoclonal antibody reduces liver fibrosis development. Hepatol Res. 2010;40(11):1128\u201341.","journal-title":"Hepatol Res"},{"issue":"6","key":"1023_CR23","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/hep.25897","volume":"56","author":"H Park","year":"2012","unstructured":"Park H, Serti E, Eke O, et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology. 2012;56(6):2060\u201370.","journal-title":"Hepatology"},{"issue":"5","key":"1023_CR24","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/hep.26182","volume":"57","author":"S Yoshio","year":"2013","unstructured":"Yoshio S, Kanto T, Kuroda S, et al. Human blood dendritic cell antigen 3 (BDCA3)+ dendritic cells are a potent producer of interferon-\u03bb in response to hepatitis C virus. Hepatology. 2013;57(5):1705\u201315.","journal-title":"Hepatology"},{"issue":"4","key":"1023_CR25","doi-asserted-by":"crossref","first-page":"e1003316","DOI":"10.1371\/journal.ppat.1003316","volume":"9","author":"AE Stone","year":"2013","unstructured":"Stone AE, Giugliano S, Schnell G, et al. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog. 2013;9(4):e1003316.","journal-title":"PLoS Pathog"},{"issue":"19","key":"1023_CR26","doi-asserted-by":"crossref","first-page":"7944","DOI":"10.1073\/pnas.1100552108","volume":"108","author":"J Pott","year":"2011","unstructured":"Pott J, Mahlakoiv T, Mordstein M, et al. IFN-\u03bb determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A. 2011;108(19):7944\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"1023_CR27","doi-asserted-by":"crossref","first-page":"e26620","DOI":"10.1371\/journal.pone.0026620","volume":"6","author":"M Sugiyama","year":"2011","unstructured":"Sugiyama M, Tanaka Y, Wakita T, et al. Genetic variation of the IL-28B promoter affecting gene expression. PLoS One. 2011;6(10):e26620.","journal-title":"PLoS One"},{"issue":"1","key":"1023_CR28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ni.2758","volume":"15","author":"AP McFarland","year":"2014","unstructured":"McFarland AP, Horner SM, Jarret A, et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol. 2014;15(1):72\u20139.","journal-title":"Nat Immunol"},{"issue":"5","key":"1023_CR29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2010.08.020","volume":"54","author":"B Langhans","year":"2011","unstructured":"Langhans B, Kupfer B, Braunschweiger I, et al. Interferon-lambda serum levels in hepatitis C. J Hepatol. 2011;54(5):859\u201365.","journal-title":"J Hepatol"},{"issue":"3","key":"1023_CR30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1189\/jlb.0303093","volume":"74","author":"CE Harvey","year":"2003","unstructured":"Harvey CE, Post JJ, Palladinetti P, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol. 2003;74(3):360\u20139.","journal-title":"J Leukoc Biol"},{"issue":"4","key":"1023_CR31","doi-asserted-by":"crossref","first-page":"506","DOI":"10.5009\/gnl.2011.5.4.506","volume":"5","author":"CR You","year":"2011","unstructured":"You CR, Park SH, Jeong SW, et al. Serum IP-10 levels correlate with the severity of liver histopathology in patients infected with genotype-1 HCV. Gut Liver. 2011;5(4):506\u201312.","journal-title":"Gut Liver"},{"issue":"6","key":"1023_CR32","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/hep.24588","volume":"54","author":"CD Fingas","year":"2011","unstructured":"Fingas CD, Bronk SF, Werneburg NW, et al. Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011;54(6):2076\u201388.","journal-title":"Hepatology"},{"issue":"5","key":"1023_CR33","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jhep.2006.11.011","volume":"46","author":"E Patsenker","year":"2007","unstructured":"Patsenker E, Popov Y, Wiesner M, et al. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol. 2007;46(5):878\u201387.","journal-title":"J Hepatol"},{"issue":"6","key":"1023_CR34","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/hep.21407","volume":"44","author":"M Lagging","year":"2006","unstructured":"Lagging M, Romero AI, Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. 2006;44(6):1617\u201325.","journal-title":"Hepatology"},{"issue":"1","key":"1023_CR35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/hep.24056","volume":"53","author":"JM Darling","year":"2011","unstructured":"Darling JM, Aerssens J, Fanning G, et al. Quantitation of pretreatment serum interferon-\u03b3-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology. 2011;53(1):14\u201322.","journal-title":"Hepatology"},{"issue":"2","key":"1023_CR36","doi-asserted-by":"crossref","first-page":"e17232","DOI":"10.1371\/journal.pone.0017232","volume":"6","author":"M Lagging","year":"2011","unstructured":"Lagging M, Askarieh G, Negro F, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One. 2011;6(2):e17232.","journal-title":"PLoS One"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-014-1023-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-014-1023-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-014-1023-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T02:38:13Z","timestamp":1559097493000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-014-1023-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,14]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["1023"],"URL":"https:\/\/doi.org\/10.1007\/s00535-014-1023-2","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,14]]}}}